

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)



(10) International Publication Number
WO 2025/199134 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/519* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2025/020419

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
18 March 2025 (18.03.2025)

Published:

— with international search report (Art. 21(3))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/567,124 19 March 2024 (19.03.2024) US
24305504.3 02 April 2024 (02.04.2024) EP
63/680,810 08 August 2024 (08.08.2024) US

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **DA CRUZ, Henri**; c/o Sanofi, Patent De-
partment, 46 avenue de la Grande Armée, 75017 Paris
(FR). **JEANJEAN, Audrey**; c/o Sanofi, Patent Depart-
ment, 46 avenue de la Grande Armée, 75017 Paris (FR).
CHU, Katherine; c/o Sanofi, Patent Department, 450 Wa-
ter Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **SLADE, Rachel M.** et al.; 245 First Street, 18th
Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: FORMULATIONS OF 2-[(3R)-2-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-
L-YL]PIPERIDINE-L-CARBONYL]-4-METHYL-4[4-(OXETAN-3-YL)PIPERAZIN-L-YL]-PENT-2-ENENITRILE

(57) Abstract: Disclosed herein are novel formulations of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrim-
idin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile, including formulations including vari-
ous solid forms thereof. Also disclosed are processes for preparing formulations of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-
phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile.



WO 2025/199134 A1